Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 134 posts found.

novartis_outside_1

Novartis lung cancer combo receives FDA approval

June 23, 2017
Medical Communications, Sales and Marketing NSCLC, Novartis

Novartis has revealed that its drug Tafinlar (dabrafenib) has received approval from the FDA for use in combination with Mekinist …

News
pfizer_finland_hq

Pfizer drug beats AZ rival in halting lung cancer

June 6, 2017
Manufacturing and Production, Research and Development NSCLC, Pfizer

New data from late-stage trials suggests that Pfizer’s dacomitinib beat out AstraZeneca’s rival treatment Iressa (gefitinib) at halting the progression …

News
novartis_outside_1

FDA approves Novartis’ Zykadia as first-line lung cancer treatment

May 30, 2017
Manufacturing and Production, Sales and Marketing FDA, NSCLC, Novartis

The FDA has announced it has approved Novartis’ Zykadia (ceritinib) as a first line treatment in the expanded indication of …

News
astrazeneca_building_white

AZ’s Tagrisso continues successes with EU approval

April 26, 2017
Research and Development, Sales and Marketing AstraZeneca, EU, European Commission, NSCLC, Tagrisso

More good news for AstraZeneca’s Tagrisso (osimertinib), as the company announces that the European Commission has granted the drug full …

News
european_commission

Novartis combo expands into lung cancer with EU approval

April 4, 2017
Manufacturing and Production, Sales and Marketing NSCLC, Novartis, Tafinlar, mekinist

Novartis has announced that its Tafinlar (dabrafenib) and Mekinist (trametinib) drug combo has been approved by the European Commission (EC) …

News
shutterstock_291014192

Asia-Pacific NSCLC market to more than double to $6.2bn by 2023

March 21, 2017
Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific …

News
keytruda1

NICE knocks back MSD’s Keytruda for lung cancer indication

February 28, 2017
Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …

News
novartis_window

Novartis’ drug doubly effective as chemotherapy for treating lung cancer

December 8, 2016
NSCLC, Novartis, chemotherapy

Novartis have released that its drug, Zykadia, in Phase III trials, was twice as effective at slowing progression in advanced …

News
merck_and_co

MSD’s Keytruda given first FDA approval for first line treatment

October 25, 2016
Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo

MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …

News

Merck KGaA and Pfizer team up with Debiopharm in lung cancer treatment

October 21, 2016
Medical Communications Debiopharm, Merck KGaA, NSCLC, Pfizer, lung cancer

Debiopharm International, the Swiss-based global biopharmaceutical group of five companies, announced that it would be entering into an agreement with …

News
shutterstock_159488225

Vaxon Biotech completes enrollment for mid-stage trial of lung cancer vaccine

March 16, 2016
Research and Development, Sales and Marketing NSCLC, immuno-oncology, vaxon biotech

Vaxon Biotech on Wednesday said it has completed the enrollments for mid-stage trials of its vaccine to treat non-small-cell lung …

News
xalkori

FDA approves Pfizer sNDA for Xalkori

March 14, 2016
Research and Development, Sales and Marketing Cancer, EMA, NSCLC, Pfizer, Xalkori (crizotinib)

The US FDA has approved Pfizer’s supplemental new drug application (sNDA) for its kinase inhibitor Xalkori in treating patients with …

News
AZ sign

AstraZeneca’s Tagrisso gets EU lung cancer sign-off

February 4, 2016
Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib

The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …

News
Xalkori

Pfizer lung cancer treatment gets expanded EU approval

December 1, 2015
Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer

Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …

News
Chest x ray

Lilly cancer drug gets US approval

November 26, 2015
NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology

Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026